Chapter 13. Tumour Hypoxia: Malignant Mediator

  1. Sotiris Missailidis
  1. Jill L. O'Donnell,
  2. Aoife M. Shannon and
  3. David Bouchier-Hayes

Published Online: 7 NOV 2008

DOI: 10.1002/9780470697047.ch13

Anticancer Therapeutics

Anticancer Therapeutics

How to Cite

O'Donnell, J. L., Shannon, A. M. and Bouchier-Hayes, D. (2008) Tumour Hypoxia: Malignant Mediator, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch13

Editor Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Author Information

  1. RCSI Education and Research Unit, Beaumont Hospital, Dublin, Ireland

Publication History

  1. Published Online: 7 NOV 2008
  2. Published Print: 21 NOV 2008

ISBN Information

Print ISBN: 9780470723036

Online ISBN: 9780470697047



  • tumour hypoxia - malignant mediator;
  • hypoxia-inducible factor 1 (HIF-1);
  • aryl hydrocarbon receptor nuclear translocator (ARNT);
  • Von Hippel–Lindau protein (pVHL);
  • HIF-1α expression and oncogene genetic alterations;
  • HIF-1 inducing hTERT (human telomerase catalytic sub-unit);
  • HIF-1 therapeutics;
  • Recombinant human Epo (rHuEpo) - clinical cancer therapeutic agent;
  • tumour progression and resistance hypoxia


This chapter contains sections titled:

  • Introduction

  • Hypoxia Inducible Factor-1 and Hypoxia

  • HIF-1α Post-translational Changes

  • How Genetics Can Modify HIF

  • How Tumours Overcome Hypoxia with HIF-1

  • HIF-1 Therapeutics

  • Conclusion

  • References